ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ENVB Enveric Biosciences Inc

0.80
-0.10 (-11.11%)
May 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 210,204
Bid Price 0.81
Ask Price 0.95
News (1)
Day High 0.885

Low
0.649

52 Week Range

High
6.98

Day Low 0.84
Company Name Stock Ticker Symbol Market Type
Enveric Biosciences Inc ENVB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.10 -11.11% 0.80 00:00:09
Open Price Low Price High Price Close Price Prev Close
0.87 0.84 0.885 0.84 0.90
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
660 210,204 $ 0.8654475 $ 181,921 - 0.649 - 6.98
Last Trade Time Type Quantity Stock Price Currency
19:59:58 35 $ 0.8123 USD

Enveric Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.95M 2.32M - 0 -17.46M -7.52 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Enveric Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ENVB Message Board. Create One! See More Posts on ENVB Message Board See More Message Board Posts

Historical ENVB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.8990.9450.7830.8646007668,919-0.099-11.01%
1 Month0.921.030.7830.95873911,247,236-0.12-13.04%
3 Months0.992.920.7831.345,006,975-0.19-19.19%
6 Months1.592.920.6491.332,434,570-0.79-49.69%
1 Year1.406.980.6492.482,105,996-0.60-42.86%
3 Years1.9114.870.15511.991,701,378-1.11-58.12%
5 Years6.0014.870.15512.582,059,648-5.20-86.67%

Enveric Biosciences Description

Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).